File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effectiveness of electroacupuncture and electroconvulsive therapy as additional treatment in hospitalized patients with schizophrenia: a retrospective controlled study

TitleEffectiveness of electroacupuncture and electroconvulsive therapy as additional treatment in hospitalized patients with schizophrenia: a retrospective controlled study
Authors
Keywordselectroconvulsive therapy (ECT)
acupuncture
schizophrenia
positive symptoms
negative symptoms
Issue Date2019
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/psychology
Citation
Frontiers in Psychology, 2019, v. 10, article no. 2306 How to Cite?
AbstractElectroacupuncture (EA) and electroconvulsive therapy (ECT) are often used in the management of schizophrenia. This study sought to determine whether additional EA and ECT could augment antipsychotic response and reduce related side effects. In this retrospective controlled study, 287 hospitalized schizophrenic patients who received antipsychotics (controls, n = 50) alone or combined with EA (n = 101), ECT (n = 55) or both (EA + ECT, n = 81) were identified. EA and ECT were conducted for 5 and 3 sessions per week, respectively, with a maximum of 12 sessions for ECT during hospitalization. The Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the severity of psychotic symptoms. Clinical response on SAPS and SANS, weight gain, and adverse events were compared. Survival analysis revealed that the ECT and EA + ECT groups had markedly greater clinical response rate than controls on SAPS [72.7 and 90.1% vs. 64.0%; relative risk (RR), 1.974 and 2.628, respectively, P ≤ 0.004] and on SANS (67.3 and 70.4% vs. 42.0%; RR, 1.951 and 2.009, respectively, P ≤ 0.015). A significantly greater response rate on SANS than controls was also observed in the EA group (64.4% vs. 42.0%; RR = 1.938, P = 0.008). EA-containing regimens remarkably reduced weight gain and incidences of headache, insomnia, dry mouth, and electrocardiographic abnormalities. These results suggest that EA and ECT can serve as additional treatment for enhancing antipsychotic response and reduce the side effects in hospitalized patients with schizophrenia. Clinical Trial Registration: http://www.chictr.org.cn/showprojen.aspx?proj=38901, identifier ChiCTR1900023563.
Persistent Identifierhttp://hdl.handle.net/10722/284273
ISSN
2023 Impact Factor: 2.6
2023 SCImago Journal Rankings: 0.800
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJia, J-
dc.contributor.authorShen, J-
dc.contributor.authorLiu, FH-
dc.contributor.authorWong, HK-
dc.contributor.authorYang, XJ-
dc.contributor.authorWu, QJ-
dc.contributor.authorZhang, H-
dc.contributor.authorWang, HN-
dc.contributor.authorTan, QR-
dc.contributor.authorZhang, ZJ-
dc.date.accessioned2020-07-20T05:57:25Z-
dc.date.available2020-07-20T05:57:25Z-
dc.date.issued2019-
dc.identifier.citationFrontiers in Psychology, 2019, v. 10, article no. 2306-
dc.identifier.issn1664-1078-
dc.identifier.urihttp://hdl.handle.net/10722/284273-
dc.description.abstractElectroacupuncture (EA) and electroconvulsive therapy (ECT) are often used in the management of schizophrenia. This study sought to determine whether additional EA and ECT could augment antipsychotic response and reduce related side effects. In this retrospective controlled study, 287 hospitalized schizophrenic patients who received antipsychotics (controls, n = 50) alone or combined with EA (n = 101), ECT (n = 55) or both (EA + ECT, n = 81) were identified. EA and ECT were conducted for 5 and 3 sessions per week, respectively, with a maximum of 12 sessions for ECT during hospitalization. The Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the severity of psychotic symptoms. Clinical response on SAPS and SANS, weight gain, and adverse events were compared. Survival analysis revealed that the ECT and EA + ECT groups had markedly greater clinical response rate than controls on SAPS [72.7 and 90.1% vs. 64.0%; relative risk (RR), 1.974 and 2.628, respectively, P ≤ 0.004] and on SANS (67.3 and 70.4% vs. 42.0%; RR, 1.951 and 2.009, respectively, P ≤ 0.015). A significantly greater response rate on SANS than controls was also observed in the EA group (64.4% vs. 42.0%; RR = 1.938, P = 0.008). EA-containing regimens remarkably reduced weight gain and incidences of headache, insomnia, dry mouth, and electrocardiographic abnormalities. These results suggest that EA and ECT can serve as additional treatment for enhancing antipsychotic response and reduce the side effects in hospitalized patients with schizophrenia. Clinical Trial Registration: http://www.chictr.org.cn/showprojen.aspx?proj=38901, identifier ChiCTR1900023563.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/psychology-
dc.relation.ispartofFrontiers in Psychology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectelectroconvulsive therapy (ECT)-
dc.subjectacupuncture-
dc.subjectschizophrenia-
dc.subjectpositive symptoms-
dc.subjectnegative symptoms-
dc.titleEffectiveness of electroacupuncture and electroconvulsive therapy as additional treatment in hospitalized patients with schizophrenia: a retrospective controlled study-
dc.typeArticle-
dc.identifier.emailWong, HK: hkwong@hku.hk-
dc.identifier.emailYang, XJ: yangxj@hku.hk-
dc.identifier.emailZhang, ZJ: zhangzj@hkucc.hku.hk-
dc.identifier.authorityZhang, ZJ=rp01297-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fpsyg.2019.02306-
dc.identifier.scopuseid_2-s2.0-85074539300-
dc.identifier.hkuros311333-
dc.identifier.volume10-
dc.identifier.spagearticle no. 2306-
dc.identifier.epagearticle no. 2306-
dc.identifier.isiWOS:000497506100001-
dc.publisher.placeSwitzerland-
dc.identifier.issnl1664-1078-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats